Home » Newsletters » BioWorld Science

BioWorld Science

July 10, 2012

View Archived Issues

Scientists at Actelion Pharmaceuticals patent new FPR2/ALX receptor agonists

New MPGES-1 inhibitors designed in Germany

New long-acting drug is well tolerated as once-weekly growth hormone replacement therapy

PARP-1/2 inhibitor shows promising safety profile in patients with cancer

Lupin presents novel GLP-1 receptor modulators

New agents for cancer reported by Kasina Laila Innova Pharmaceuticals

First-in-human study of EP-100 complete

Ampio Pharmaceticals discloses data from Optina trial

Novel DPP IV inhibitors prepared

OncoSec launches new phase II OMS ElectroImmunotherapy trial

DNAzyme is effective in models of skin cancer

FDA grants priority review for Xarelto applications

Proteostasis Therapeutics discloses novel prosteostasis regulators

ACT clear to proceed with dry AMD trial

Repros reaches agreement with FDA on pivotal Androxal studies

Titan Pharmaceuticals completes study of nonfluctuating dopamine receptor agonist drug

Lux Biosciences completes enrollment in phase III trial in noninfectious uveitis

TONIX reports encouraging pharmacokinetic data on TNX-102

Potential biomarker of AMD identified

Acusphere gives update on MAA for Imagify

FDA places clinical hold on IB-1001 trials

Pergamum reports topline data from phase II trial in prevention of postsurgical adhesions

Sanofi withdraws MAA for anticoagulant drug

Phase III Halaven study in new breast cancer indication does not meet primary endpoints

Xiaflex approved in Canada

Norwegian government awards grant to Bionor

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...